New Recruiting Trial: Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
WHY IT MATTERS
This trial offers a potential new treatment option for people with HIV-related Kaposi Sarcoma who haven't responded to standard immune-boosting treatments, addressing a significant gap in care for this vulnerable population.
Researchers are testing a new drug called CYT107 to help people with HIV who have Kaposi Sarcoma (a type of cancer) and whose immune systems aren't responding well to treatment. CYT107 is designed to boost the immune system to help fight the cancer. This is a Phase 2 trial, meaning it's testing whether the drug works and is safe in a larger group of people. The trial is now accepting patients and will start in April 2026.
NCT ID: NCT07308886 Title: Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV) Status: RECRUITING Phase: PHASE2 Sponsor: National Cancer Institute (NCI) Start date: 2026-04-05 URL: https://clinicaltrials.gov/study/NCT07308886 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you have HIV and Kaposi Sarcoma with immune non-response, contact your doctor immediately to discuss whether you meet eligibility criteria and can enroll in this recruiting trial at clinicaltrials.gov/study/NCT07308886.